BARCELONA, Spain and DÜSSELDORF, Germany, July 24, 2026 -- Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has...


Athersys is a clinical-stage biotechnology company that has established a pipeline of therapeutic product development programs in multiple disease indications. The company’s product portfolio consists of MultiStem, a non-embryonic stem cell-based approach for treating disease indications in the areas of inflammatory and immune, neurological and cardiovascular disease.